Literature DB >> 3893668

Early-stage Hodgkin's disease: current approaches to treatment.

J J Rusthoven, R MacKenzie.   

Abstract

Most patients with early-stage Hodgkin's disease can now be cured by one of several therapeutic approaches. This review highlights the developments in the diagnosis and treatment of the disease that have led to long-term survival rates greater than 90%. Past and present radio-therapy (RT) planning and treatment practices are discussed in the context of both clinical and pathological staging. The role of initial bimodal therapy (RT and chemotherapy [CT]) and the use of CT in patients who suffer relapse after initial treatment with RT alone are reviewed. On the basis of prognostic factors, subgroups of patients for whom bimodal therapy is recommended, including those with a bulky mediastinal mass, have now been identified. Although treatment is highly successful, debilitating consequences of RT and CT, such as infertility, infection and second malignant diseases, remain. Newer treatment regimens may reduce morbidity and have similar or better long-term results with respect to survival and quality of life.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893668      PMCID: PMC1346147     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  15 in total

Review 1.  ABVD chemotherapy in the treatment of Hodgkin's disease.

Authors:  G Bonadonna; A Santoro
Journal:  Cancer Treat Rev       Date:  1982-03       Impact factor: 12.111

Review 2.  Non-Hodgkin's lymphoma occurring after Hodgkin's disease. Four new cases and a review of the literature.

Authors:  C Jacquillat; D Khayat; J P Desprez-Curely; M Weil; C Brocheriou; G Auclerc; N Chamseddine; J Bernard
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

3.  Prognostic significance of mediastinal mass in adult Hodgkin's disease.

Authors:  P J Schomberg; R G Evans; M J O'Connell; W L White; P M Banks; D M Ilstrup; J D Earle
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

Review 4.  Infections in patients with Hodgkin's disease: a clinical study of 300 consecutive adult patients.

Authors:  D T Notter; P L Grossman; S A Rosenberg; J S Remington
Journal:  Rev Infect Dis       Date:  1980 Sep-Oct

5.  Results of treating Hodgkin's disease without a policy of laparotomy staging.

Authors:  D E Bergsagel; R E Alison; H A Bean; T C Brown; R S Bush; R M Clark; T Chua; D Dalley; G DeBoer; M Gospodarowicz; R Hasselback; D Perrault; D F Rideout
Journal:  Cancer Treat Rep       Date:  1982-04

6.  Stage I and II Hodgkin's disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP.

Authors:  F B Hagemeister; L M Fuller; W S Velasquez; J A Sullivan; L North; J J Butler; D A Johnston; C C Shullenberger
Journal:  Cancer Treat Rep       Date:  1982-04

7.  The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease.

Authors:  M R Cooper; T F Pajak; A J Gottlieb; A S Glicksman; N Nissen; F Richards; C Bloomfield; J F Holland
Journal:  J Clin Oncol       Date:  1984-07       Impact factor: 44.544

8.  The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy.

Authors:  M Tubiana; M Henry-Amar; M Hayat; M Burgers; M Qasim; R Somers; W Sizoo; E van der Schueren
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-02       Impact factor: 7.038

9.  Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.

Authors:  M F da Cunha; M L Meistrich; L M Fuller; J H Cundiff; F B Hagemeister; W S Velasquez; P McLaughlin; S A Riggs; F F Cabanillas; P G Salvador
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

10.  Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup.

Authors:  C A Coltman; D O Dixon
Journal:  Cancer Treat Rep       Date:  1982-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.